ENLeukaemia is a cancer of the blood-forming system: blood cells in the bone marrow stop maturing and crowd out the normal ones, causing weakness, bruising and frequent infections. “Blood cancer” is the everyday name for the same group of diseases. Treatment starts not with a drug but with pinning down the exact form.
Leukemia treatment in Germany (leukaemia in British spelling) follows the pace of the disease: acute forms are counted in days, chronic ones in months of monitoring. Acute leukaemia can shut down blood production within weeks, so tests and the first chemotherapy happen in one hospital stay, while chronic forms develop slowly. What a German hospital offers is not a miracle but a protocol (a phase-by-phase plan based on guidelines) and precise diagnosis.
The forms of leukaemia
Leukaemias are divided by speed into acute and chronic, and by the cell line they grew from into lymphoid and myeloid. Acute leukaemia grows from immature blasts within weeks, chronic leukaemia from partly matured cells over months or years. This gives four main forms: acute lymphoblastic (ALL), acute myeloid (AML), chronic lymphocytic (CLL) and chronic myeloid (CML) leukaemia.
The form decides the strategy. In ALL and AML, chemotherapy starts as soon as the diagnosis is confirmed. In early CLL without symptoms, watchful waiting is often right, with treatment once the disease becomes active. CML is held in check for years with tablets, mostly as an outpatient.
Acute lymphoblastic leukaemia is the commonest form in children, most often diagnosed between the ages of one and five; adults are treated on protocols of their own. It has a separate page on acute lymphoblastic leukaemia.
Confirming the diagnosis
The diagnosis rests on blood and bone marrow. A full blood count with differential and a blood film show missing cells and any immature blasts. To confirm it, a fine needle draws a little marrow from the back of the pelvic bone under local anaesthetic (aspiration), causing a brief dragging pain; if too little comes, or the structure must be seen, a thicker needle takes a tiny core of bone, the trephine biopsy.
Immunophenotyping then reads surface proteins to show the cell line. Cytogenetics finds rearranged chromosomes such as the Philadelphia chromosome, whose BCR-ABL gene makes cells divide non-stop; most people with CML have it. Molecular tests detect small mutations, in AML above all in FLT3 and NPM1. The results shape the drug choice (FLT3 means adding a targeted drug), the risk group (NPM1 without a particular FLT3 change usually means favourable) and the transplant decision.
Minimal residual disease (MRD) means leukaemia cells left after treatment in numbers too small to see under the microscope; very sensitive tests detect even single cells. It is checked at fixed points: if none are found, treatment continues as planned; if cells persist or rise, it is stepped up or a transplant considered earlier. The German Cancer Research Centre’s Krebsinformationsdienst explains these tests (in German).
What the treatment consists of
Leukaemia is treated with chemotherapy, targeted drugs, cell therapy and transplant; in acute forms chemotherapy in phases is the backbone. Induction, the most intensive weeks, aims to clear the marrow of leukaemia cells; consolidation destroys what remains, and in ALL long maintenance with tablets follows. With almost no infection-fighting cells during induction, the patient stays in hospital, often in a single room with filtered air, receiving antibiotics and transfusions. More on chemotherapy for leukaemia.
Targeted drugs strike a specific fault in the leukaemia cell. In CML, tyrosine kinase inhibitors — daily tablets that block the BCR-ABL protein — turn the disease into a manageable chronic condition; they are taken for years, with regular blood checks. In CLL, when treatment is needed, targeted tablets and antibodies are used; antibodies recognise a marker on leukaemia cells and help the immune system destroy them.
For relapsed or resistant B-cell ALL, CAR-T cell therapy is an option. The patient’s own T cells are given a receptor in the laboratory that recognises leukaemic B cells, then returned by drip to destroy the leukaemia. In Europe it is approved for children, young adults and adults. Only centres equipped to treat severe immune reactions may give it, under requirements set in Germany by the Federal Joint Committee (G-BA). More on CAR-T cell therapy.
When a bone marrow transplant is needed
A donor (allogeneic) transplant is offered when the risk of relapse after chemotherapy alone is high: with unfavourable genetics or a poor response, after a relapse, or in CML when tablets stop working. It replaces the patient’s blood production with a donor’s: high-dose treatment destroys the diseased marrow, and donor stem cells build new blood and immunity that also attacks surviving leukaemia cells. The decision follows the risk group, not preference: the transplant itself is risky, and at low risk chemotherapy is enough.
The donor search starts with brothers and sisters, then moves to national and international registries. The main risk after conditioning, the high-dose treatment, is graft-versus-host disease: donor immune cells attack the patient’s skin and organs, so immune-suppressing drugs are given to prevent and treat it. New blood cells appear after two to four weeks, but the first three to six months are the most dangerous, so check-ups are frequent and the patient must live near the hospital. More on bone marrow transplant.
Children with leukaemia
Leukaemia is the commonest childhood cancer, nearly always acute and most often ALL. Children are treated in specialist centres on international protocols shared with other European countries, and a parent can stay in hospital with the child.
Treatment is long: for ALL about two years — roughly six months of intensive courses with frequent admissions, then about eighteen months of milder, mostly outpatient therapy. Psychologists and social workers support the family, and hospital-school teachers teach children on the ward. Follow-up continues for years to catch any relapse or late effects early. More on paediatric oncology.
Frequently asked questions
How is leukaemia treated today?
It depends on the form and its genetics. Acute forms receive intensive chemotherapy in phases, plus targeted drugs for certain mutations and a donor transplant when relapse risk is high. CML is controlled with tablets; CLL is often watched at first, then treated with targeted tablets and antibodies. Relapsed B-cell ALL may receive CAR-T cells.
Can leukaemia be cured?
That depends on the form. Acute leukaemias are treated with the aim of cure, which many patients achieve; the chances depend on genetics, response to treatment, age and general health. CML and CLL are usually not cured, but modern drugs keep them in check for years. Only a full assessment shows what to expect.
Can treatment start at home and continue in Germany?
Yes, if that is safer. Acute leukaemia should not go untreated for the sake of travel, so the first courses are sometimes given locally and the patient comes to Germany for later phases or a transplant. The treating doctor and a German haematologist decide together from the records, including genetic and MRD results.
How AlenMed arranges treatment
AlenMed arranges treatment around the pace of the disease, because leukaemia often means moving fast. A haematologist at a partner hospital reviews the letters and blood results remotely; AlenMed chooses a haematology unit suited to the form and stage, arranges an urgent appointment and the visa invitation, and provides accompaniment and an interpreter.
The cost estimate comes from the hospital and, in leukaemia, is revised as treatment goes on: nobody knows in advance how many courses will be needed, how long recovery will take or whether a transplant will follow, so it is updated before each new phase. More on the cost of leukaemia treatment.
This material is for information only and is not an offer; the form of the disease and the treatment plan are decided by a doctor at an in-person consultation.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
